What changed: NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia
Every dated change on the records linked to NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval1Trial result3Milestone5This record1
September 2026 · 1
2025 · 3
- 2025ApprovalZiftomenibZiftomenib approved in US
Relapsed/refractory NPM1-mutated AML with no satisfactory alternative
- 2025Trial resultKOMET-001KOMET-001 reported
CR 23%, ORR 33%, median OS 6.
- 2025MilestoneKOMET-001Ziftomenib and revumenib approved for relapsed NPM1-mutated AML
A milestone in how this cancer is treated.